AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$TWST

Leproust Emily M. sold $282K of TWST

Leproust Emily M. (Chief Executive Officer) sold 2,302 shares of Twist Bioscience Corp (TWST) at $122.62 ($0.28M total) on 2026-09-08.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Sep 10, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

While the sale amount is modest, CEO-level insider activity can influence short-term sentiment.

02

Market read

The filing provides fresh data on insider holdings, useful for short-term traders monitoring executive confidence.

03

What to watch

Potential tax planning or diversification motives behind the sale.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

CEO Emily M. Leproust sold 2,302 shares of Twist Bioscience for $282,280, reducing her holdings to 768,427 shares.

Expected impact

Modest short-term dip, likely within 1-2% range.

Evidence & confidence

Sale size is modest relative to market cap, but CEO insider sales are closely watched by traders.

Market effects

Sector

Minimal impact on the biotech sequencing sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Twist Bioscience Corp

    Biotechnology company specializing in DNA synthesis.

  • Person
    Emily M. Leproust

    Chief Executive Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min
SEP 16
$TWSTMed

Why is Twist Bioscience stock rallying today?

Twist Bioscience (TWST) stock rose 3.7% after joining Eli Lilly's TuneLab platform as a preferred antibody data provider. The deal supports Twist's AI-driven life science strategy, following record Q3 revenue and raised guidance. The stock is near its 52-week high, with NASDAQ and S&P 500 also gaining.

investing.com2 min